E.N. Onyeozili et al. / Tetrahedron 69 (2013) 849e860
857
2.88 (d, J¼13.5 Hz, 1H), 2.83 (d, J¼13.0 Hz, 1H), 0.92 (s, 9H), 0.05 (s,
9H). 13C NMR (125 MHz, CDCl3)
137.9,136.1,130.6 (2C),129.2,127.7
Compound 22: 1H NMR (500 MHz, CDCl3)
d
7.29e7.20 (m, 5H),
d
3.30 (d, J¼10.2 Hz, 1H), 2.42e2.25 (m, 3H), 0.94 (d, J¼6.3 Hz, 3H),
(2C), 126.3, 70.0, 43.1, 32.8, 29.9, ꢀ4.2. IR (film) 3534, 3028, 2959,
0.74e0.67 (m, 1H), 0.63 (d, J¼6.8 Hz, 3H), 0.61e0.54 (m, 1H), ꢀ0.11
1248, 843 cmꢀ1. HRMS (EI) m/z 258.1820 [(MꢀH2O)þ; calcd for
(s, 9H). 13C NMR (126 MHz, CDCl3)
d 211.7, 138.4, 128.7 (2C), 128.6
C
17H26Si, 258.1804].
(2C), 127.0, 66.4, 37.8, 30.7, 21.7, 20.4, 9.9, ꢀ1.9. IR (neat) 1715 cmꢀ1
.
Compound 13: 1H NMR (500 MHz, CDCl3)
d
7.25 (m, 2H), 7.19 (m,
HRMS (CI) m/z 262.1755 [(M)þ; calcd for C16H26OSi, 262.1753].
3H), 6.11 (dd, J¼10.0, 18.5 Hz, 1H), 5.25 (dd, J¼0.5, 18.0 Hz, 1H), 5.03
(t, J¼3.0 Hz, 1H), 1.93 (dd, J¼2.5, 9.0 Hz, 1H), 1.70 (d, J¼3.5 Hz, 1H),
4.3.7. Wittig rearrangements of compound 23. Applying the general
procedure B to compound 23 (anti/syn¼1:1) (66 mg, 0.282 mmol,
1 equiv) and n-BuLi (1.6 M in cyclohexane, 0.53 mL, 3 equiv) at
ꢀ78 ꢁC and then at ꢀ30 ꢁC for 3 h, after purification by silica gel
column chromatography (3% EtOAc in hexanes), afforded 16.3 mg
(26%) of 24, 10.2 mg (14%) of 25 as colorless oils, and 7.5 mg of
a mixture of anti-23 and 26 (1:9 ratio). An analytical sample of 26
was obtained by column chromatography eluting with hexanes.
0.97 (s, 9H), 0.00 (s, 9H). 13C NMR (125 MHz, CDCl3)
d 145.3, 142.1,
136.3, 127.8 (2C), 126.9 (2C), 126.2, 73.6, 65.0, 33.0, 28.9, ꢀ1.2. IR
(film) 3422, 2955, 1246, 837 cmꢀ1. HRMS (EI) m/z 258.1791
[(MꢀH2O)þ; calcd for C17H26Si, 258.1804].
4.3.4. Wittig rearrangements of compound 14. Applying general
procedure B to 360 mg (1.53 mmol) of 14 and 1.8 mL (2.30 mmol) of
s-BuLi (1.3 M in cyclohexane) at ꢀ78 ꢁC overnight, afforded 162 mg
(46%) of a 1.68:1 mixture of 15 and 16 as a colorless oil.
Compound 24: 1H NMR (600 MHz, CDCl3)
d
7.08 (d, J¼7.8 Hz,
2H), 7.02 (d, J¼8.4 Hz, 2H), 2.59 (m, 1H), 2.51 (ddd, A of ABX system,
J¼6.0, 9.0, 16.8 Hz, 1H), 2.41 (ddd, B of ABX system, J¼6.0, 9.0,
17.4 Hz, 1H), 2.30 (s, 3H), 1.80 (m, 1H), 1.72 (m, 1H), 1.20 (d, J¼6.6 Hz,
Compound 15: 1H NMR (300 MHz, CDCl3)
d 7.33e7.12 (m, 5H),
2.67e2.57 (m, 1H), 2.54e2.41 (m, 1H), 1.89e1.67 (m, 2H), 1.24e1.21
(d, J¼7.1 Hz, 3H), 0.11 (s, 9H). 13C NMR (125 MHz, CDCl3)
d
248.2,
3H), 0.12 (s, 9H). 13C NMR (151 MHz, CDCl3)
d 248.2, 143.6, 135.5,
146.6, 128.4, 127.0, 126.0, 46.4, 39.3, 30.2, 22.4, ꢀ3.2. IR (neat)
1643 cmꢀ1. HRMS (EI) m/z 233.1358 [(MꢀH)þ; calcd for C14H21OSi,
233.1362].
129.1 (2C), 126.9 (2C), 46.5, 38.9, 30.3, 22.5, 21.0, ꢀ3.2. IR (film)
2959, 1643, 1250, 844 cmꢀ1. HRMS (EI) m/z 248.1595 [(M)þ; calcd
for C15H24OSi, 248.1596].
Compound 16: 1H NMR (300 MHz, CDCl3)
d
7.33e7.19 (m, 5H),
Compound 25: 1H NMR (500 MHz, CDCl3)
d
7.11 (d, J¼8.0 Hz,
3.82e3.75 (q, J¼6.9 Hz, 1H), 2.34e2.28 (m, 2H), 1.38 (d, J¼6.9 Hz,
2H), 7.08 (d, J¼8.5 Hz, 2H), 3.74 (q, J¼7.0 Hz, 1H), 2.30 (m, 6H), 1.35
(d, J¼7.0 Hz, 3H), 0.71 (ddd, A of ABX system, J¼6.5, 10.0, 15.0 Hz,
1H), 0.60 (ddd, B of ABX system, J¼6.5, 9.0, 14.0 Hz, 1H), 0.11 (s, 9H).
3H), 0.77e0.55 (m, 2H), ꢀ0.11 (s, 9H). 13C NMR (126 MHz, CDCl3)
d
211.8, 140.8, 128.8 (2C), 127.8 (2C), 127.0, 52.3, 35.6, 17.7, 10.3, ꢀ1.9.
IR (neat) 1717, 1601 cmꢀ1. HRMS (CI) m/z 234.1466 [(M)þ; calcd for
14H22OSi, 234.1440].
13C NMR (126 MHz, CDCl3)
d 212.0, 137.9, 136.7, 129.5 (2C), 127.7
C
(2C), 51.9, 35.5, 21.0, 17.7, 10.4, ꢀ1.9. IR (film) 2955, 1716, 1456, 1250,
837 cmꢀ1. HRMS (EI) m/z 233.1363 [(MꢀCH3)þ; calcd for C14H21OSi,
233.1362].
4.3.5. Wittig rearrangements of compound 17. Applying general
procedure B to 165 mg (0.638 mmol) of 17 and 1.6 mL of n-BuLi
(2.55 mmol, 4 equiv, 1.6 M in hexanes) at ꢀ78 ꢁC, allowing the re-
action to warm to ꢀ30 ꢁC and stirring at this temperature for about
48 h, after purification by column chromatography on silica gel
afforded 45 mg (32%) of a 4.53:1 mixture of 18 and 19 as light
yellow oils. Note: the reported yield is based on 2.64:1 di-
astereomeric ratio of anti/syn 17.
Compound 26: (1:0.7 mixture of diastereomers) 1H NMR
(500 MHz, CDCl3)
d
7.09 (m, 8H), 6.97 (d, J¼8.0 Hz, 2.8H), 6.91 (d,
J¼8.5 Hz, 2.8H), 2.90 (m, 1.4H), 2.72 (m, 2H), 2.32 (s, 6H), 2.25 (s,
4.2H), 1.20 (m, 4.2H), 0.98 (m, 6H). 13C NMR (126 MHz, CDCl3)
d
143.6, 142.8, 135.4, 135.0, 128.9, 128.5, 127.7, 127.5, 46.8, 45.8, 21.2,
21.0, 20.9, 17.8. IR (film) 3021, 2961, 1514, 1452, 817 cmꢀ1. HRMS (EI)
m/z 238.1724 [(M)þ; calcd for C18H22, 238.1722].
Compound 18: 1H NMR (500 MHz, CDCl3)
d 7.34e7.16 (m, 5H),
5.78e5.60 (m, 1H), 5.00e4.89 (m, 2H), 2.58e2.52 (m, 1H),
2.50e2.45 (m, 1H), 2.39e2.31 (m, 3H), 2.00e1.93 (m, 1H), 1.72e1.64
4.3.8. Wittig rearrangements of anti/syn E-30. Applying represen-
tative procedure B to 235 mg (0.946 mmol) of E-30 (anti/syn¼1.5:1)
and 2.36 mL of n-BuLi (3.78 mmol, 4 equiv, 1.6 M in hexanes) in THF
(12 mL) at ꢀ30 ꢁC for 44 h. After purification by column chroma-
tography on silica gel (30% CH2Cl2 in hexanes) 101 mg of anti E-30
(43%), 10.1 mg of 32 (16%), and 72 mg of a mixture of 31 (23%, anti/
syn¼1.9:1) and 33 (6%, anti/syn¼1.44:1) were obtained. Analytical
samples of 31 and 33 were obtained by subsequent column chro-
matography of the mixture (30% CH2Cl2 in hexanes).
(m, 1H), 0.09 (s, 9H). 13C NMR (126 MHz, CDCl3)
d 248.1,144.4,136.8,
128.4 (2C), 127.7 (2C), 126.2, 116.0, 46.1, 45.1, 41.4, 27.9, ꢀ3.2. IR
(neat) 1717, 1643 cmꢀ1. HRMS (EI) m/z 260.1595 [(M)þ; calcd for
C16H24OSi, 260.1596].
Compound 19: 1H NMR (500 MHz, CDCl3)
d 7.31e7.08 (m, 5H),
5.68e5.60 (m, 1H), 5.00e4.91 (m, 2H), 3.72 (t, J¼7.4 Hz, 1H),
2.81e2.75 (m, 1H), 2.45e2.39 (m, 1H), 2.31 (m, 2H), 0.74e0.68 (m,
1H), 0.62e0.56 (m, 1H), ꢀ0.11 (s, 9H). 13C NMR (126 MHz, CDCl3)
Compound 31 (mixture of diastereomers anti-31/syn-31,
d
210.6, 138.6, 135.9, 128.8 (2C), 128.2 (2C), 127.2, 116.6, 58.1, 36.7,
0.65:0.35 ratio): 1H NMR (600 MHz, CDCl3)
d 7.28e7.24 (m, 2H),
36.5, 10.1, ꢀ1.9. IR (neat) 1716, 1643 cmꢀ1. HRMS (EI) m/z 260.1593
7.18e7.12 (m, 3H), 2.64 (m, 0.65H), 2.61 (m, 0.65H), 2.52 (m, 0.35H),
2.46 (m, 0.35H), 2.38e2.26 (m, 2H), 1.21 (d, J¼6.6 Hz, 1.05H), 1.20 (d,
J¼7.2 Hz, 1.95H), 0.84 (d, J¼6.6 Hz, 1.05H), 0.70 (d, J¼6.6 Hz, 1.95H),
0.14 (s, 5.85H), 0.08 (s, 3.15H). 13C NMR (151 MHz, CDCl3) major
[(M)þ; calcd for C16H24OSi, 260.1596].
4.3.6. Wittig rearrangements of compound 20. Applying general
procedure B to 69.5 mg of syn-20 (0.265 mmol) and 0.33 mL of n-
BuLi (0.5296 mmol, 2 equiv) in THF (3.3 mL) at ꢀ78 ꢁC and then at
0 ꢁC for 17 h afforded a mixture (15.8 mg) of 21 and 22 in a combined
23% yield as colorless oil along with 18.6 mg of unreacted syn-20.
Column chromatography was performed with 3% EtOAc in hexanes.
diastereomer (anti-31):
d 248.6, 145.4, 128.1 (2C), 127.9 (2C), 126.0,
53.0, 44.6, 33.5, 18.2, 18.04, ꢀ3.16. Minor diastereomer (syn-31):
d
248.7, 146.3, 128.2 (2C), 127.6 (2C), 126.0, 54.0, 45.0, 33.8, 18.05,
17.4, ꢀ3.25. IR (neat) 1643 cmꢀ1. HRMS (ESI) m/z 249.1665
[(MþHþ); calcd for C15H25OSi, 249.1675].
Compound 21: 1H NMR (500 MHz, CDCl3)
d
7.26e7.03 (m, 5H),
Compound 32 (mixture of diastereomers, 0.88:0.12 ratio, rela-
tive stereochemistry not assigned): 1H NMR (600 MHz, CDCl3)
2.39e2.35 (m,1H), 2.30e2.24 (m, 1H), 2.20e2.15 (m,1H), 2.08e2.02
(m, 1H), 1.80e1.73 (m, 1H), 1.71e1.63 (m, 1H), 0.94 (d, J¼6.8 Hz, 3H),
0.68 (d, J¼6.8 Hz, 3H), 0.06 (s, 9H). 13C NMR (126 MHz, CDCl3)
d
7.26e7.14 (m, 5H), 5.72 (dd, J¼1.2, 15.6 Hz, 0.12H), 5.59 (dd, J¼1.2,
15.6 Hz, 0.88H), 5.28 (dq, J¼6.6, 15.6 Hz, 0.12H), 5.12 (dq, J¼6.6,
15.6 Hz, 0.88H), 3.04 (q, J¼7.2 Hz, 0.88H), 3.00 (q, J¼7.2 Hz, 0.12H),
1.71 (dd, J¼1.8, 6.6 Hz, 0.36H), 1.61 (dd, J¼1.2, 6.6 Hz, 2.64H), 1.32 (d,
J¼7.2 Hz, 2.64H), 1.27 (d, J¼7.2 Hz, 0.36H), 1.03 (s, 0.12H), 1.02 (s,
d
248.6, 143.8, 128.4 (2C), 128.1 (2C), 126.0, 52.4, 33.7, 25.2, 20.9,
15.3, ꢀ3.3. IR (neat) 1719, 1643 cmꢀ1. HRMS (APCI) m/z 263.1840
[(MþH)þ; calcd for C16H27OSi, 263.1831].